Mustang Bio (MBIO) Q2 2024 earnings summary

Executive summary

• Mustang Bio is a clinical-stage biopharmaceutical company focused on cell and gene therapies for hematologic cancers and solid tumors, with a pipeline centered on CAR T therapies and strategic partnerships with leading research institutions.

• The company has not generated revenue from product sales and continues to incur significant operating losses, with an accumulated deficit of $394.4 million as of June 30, 2024.

• Substantial doubt exists regarding Mustang Bio's ability to continue as a going concern, with cash and cash equivalents of $4.3 million expected to fund operations only into the fourth quarter of 2024.

• Recent strategic actions include an 81% workforce reduction, termination of several license agreements, and asset repurchase following a failed facility sale due to national security concerns.

Financial highlights

• Net loss for Q2 2024 was $8.2 million, a 49% improvement compared to $16.2 million in Q2 2023; net loss for the six months ended June 30, 2024, was $13.4 million, down from $32.9 million year-over-year.

• Operating expenses for Q2 2024 were $8.5 million, down 39% from $13.9 million in Q2 2023, driven by lower R&D and G&A costs and a $2.6 million asset impairment charge.

• Cash used in operating activities for the first half of 2024 was $7.7 million, compared to $30.2 million in the prior year period.

• Net proceeds from May and June 2024 equity offerings totaled approximately $5.3 million.

Outlook and guidance

• Cash and recent financing are expected to fund operations into Q4 2024; additional capital is required to continue as a going concern beyond that period.

• The company does not expect to initiate new pivotal clinical trials in 2024 due to limited resources and will focus on advancing priority candidates through third-party service providers as funds allow.

• Mustang Bio will continue to seek additional funding through partnerships and capital markets.